Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Circassia Initiates Phase III Trial for Cat Allergy Treatment

Published: Thursday, October 04, 2012
Last Updated: Thursday, October 04, 2012
Bookmark and Share
Cat allergy study expected to complete in summer 2014.

Imperial Innovations Group plc has announced that its portfolio company, Circassia has initiated a pivotal large-scale phase III clinical study of its ToleroMune® cat allergy treatment.

Allergies are a significant global health issue. Tens of millions of people are allergic to cats in the United States and Europe, and the disease can have a major effect on patients’ quality of life. Currently no short, simple treatment with long-lasting impact on the disease is available.

Circassia’s phase III multinational study will test safety and efficacy of the ToleroMune® treatment in approximately 1,200 subjects from the United States, Canada and Europe.

It follows positive phase II results published last month, which showed that patients had a significantly greater reduction in symptoms compared with placebo one year after the start of the study, despite only receiving a four-dose course of treatment over 12 weeks.

Allergic rhinoconjunctivitis (ARC) affects 30% of adults and 40% of children in developed countries, and the prevalence is rising.

In Continental Europe and the US, cat-allergen induced ARC, for which the ToleroMune® cat allergy treatment is designed, is one of the commonest forms and affects 10-15% of those with ARC or asthma.

Circassia has successfully completed five investment rounds to date, raising a total of £105m for the development of a range of ToleroMune® allergy treatments based on an approach of using synthetic allergen-derived peptides to induce immune tolerance by generating regulatory T-cells that suppress allergic immune responses.

Circassia has now completed phase II studies with its four leading treatments for cat, grass, house dust mite and ragweed allergies validating the Company’s scientific approach.

Susan Searle, CEO of Imperial Innovations said: “Circassia is one of our most advanced companies. We are pleased to see the Company continuing to deliver with the significant resources it has following the £72m fundraisings we led over the last 18 months. Taking its lead treatment into the advanced stages of clinical trials is a major milestone, and demonstrates the value being created in our portfolio, and the quality of the enterprises in which we invest.”

Steve Harris, Circassia’s CEO said: “Circassia’s goal is to revolutionize the treatment of allergy, and the start of this phase III study is a major strategic milestone in this endeavour. We believe our ToleroMune® technology has the potential to address the major unmet medical need for a short, simple treatment with long-lasting impact on cat allergies, and our initiation of the final phase of clinical development demonstrates our commitment to helping improve patients’ lives.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

TopiVert Starts Phase I Clinical Trial in Ulcerative Colitis
The Phase I study is being conducted at a specialist centre in London and will report in 2016.
Tuesday, May 19, 2015
Cell Medica Achieves EU Orphan Drug Designation
Orphan drug designation in the European Union for Cytovir ADV.
Tuesday, January 07, 2014
Circassia’s Cat Allergy Treatment Shows Sustained Symptom Improvement
Strong results from phase II clinical trial of Circassia.
Monday, September 16, 2013
Innovations Leads £22m Funding Round for PsiOxus Therapeutics
PsiOxus will use the funds to advance the clinical development of ColoAd1.
Tuesday, July 10, 2012
Circassia Ragweed Vaccine Achieves Phase II Clinical Development Milestone
Circassia completes phase II study of ToleroMune® ragweed allergy treatment.
Monday, March 12, 2012
Innovations Portfolio Company Circassia Achieves Key Phase II Clinical Development Milestone
Circassia has completed phase II clinical study of ToleroMune® cat allergy treatment, achieving a significant reduction in allergy symptoms and provides scientific proof of concept for the final stage of development.
Wednesday, February 16, 2011
Imperial Innovations and Kurma BioFund I conclude £0.93m seed investment in Indigix Ltd
The technology commercialisation and investment company Imperial Innovations Group plc has led a seed investment of £0.93m into its portfolio company Indigix Ltd (Indigix), alongside the Paris-based life science fund Kurma BioFund I.
Wednesday, December 01, 2010
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Automated Low Volume Dispensing Trends
Gain a better understanding of the current and future market requirements for fully automated LVD systems.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Diabetes Missing Link Discovered
Researchers from the University of Auckland have shown that beta catenin plays a vital role in the control of insulin release from the pancreas.
Study Reveals New Role for Hippo Pathway in Suppressing Cancer Immunity
Hippo pathway signaling regulates organ size by moderating cell growth, apoptosis and stem cell renewal, but dysregulation contributes to cancer development.
Biological Link between the Gut Microbiome and Parkinson’s Disease
The findings suggest that targeting the gut microbiome may provide a new approach for diagnosing and treating Parkinson’s disease.
How the Brain Recognizes Faces
Machine-learning system spontaneously reproduces aspects of human neurology.
Boosting Effectiveness of Asthma Therapy
A team of scientists from UCSF has developed a new treatment to dampen bronchospasm.
Improved Stability, Shelf Life of Protein Drugs
Study improves protein drug stability and extend their shelf life by tested a novel route for non-covalent protein modification.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!